1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A: Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians 2016, 66(4):271-289.
2. Vasen HF, Tomlinson I, Castells A: Clinical management of hereditary colorectal cancer syndromes. Nature reviews Gastroenterology & hepatology 2015, 12(2):88-97.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015, 136(5):E359-386.
4. Ulaganathan V, Kandiah M, Mohd Shariff Z: A case-control study of the association between metabolic syndrome and colorectal cancer: a comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions. Journal of gastrointestinal oncology 2018, 9(4):650-663.
5. Mohammed HA, Sulaiman GM, Anwar SS, Tawfeeq AT, Khan RA, Mohammed SAA, Al-Omar MS, Alsharidah M, Rugaie OA, Al-Amiery AA: Quercetin against MCF7 and CAL51 breast cancer cell lines: apoptosis, gene expression and cytotoxicity of nano-quercetin. Nanomedicine (Lond) 2021, 16(22):1937-1961.
6. Soofiyani SR, Hosseini K, Forouhandeh H, Ghasemnejad T, Tarhriz V, Asgharian P, Reiner Z, Sharifi-Rad J, Cho WC: Quercetin as a Novel Therapeutic Approach for Lymphoma. Oxid Med Cell Longev 2021, 2021:3157867.
7. Qi X, Xu H, Zhang P, Chen G, Chen Z, Fang C, Lin L: Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking. Evid Based Complement Alternat Med 2021, 2021:3905367.
8. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nature reviews Cancer 2004, 4(1):71-78.
9. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420(6917):860-867.
10. Salmaninejad A, Valilou SF, Soltani A, Ahmadi S, Abarghan YJ, Rosengren RJ, Sahebkar A: Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol (Dordr) 2019, 42(5):591-608.
11. Yue ZQ, Liu YP, Ruan JS, Zhou L, Lu Y: Tumor-associated macrophages: a novel potential target for cancer treatment. Chinese medical journal 2012, 125(18):3305-3311.
12. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Molecular cancer 2010, 9:273.
13. Porta C, Riboldi E, Ippolito A, Sica A: Molecular and epigenetic basis of macrophage polarized activation. Seminars in immunology 2015, 27(4):237-248.
14. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A: Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature communications 2011, 2:240.
15. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B: Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005, 22(3):371-383.
16. Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM: Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PloS one 2011, 6(8):e23317.
17. Shao LN, Zhu BS, Xing CG, Yang XD, Young W, Cao JP: Effects of autophagy regulation of tumor-associated macrophages on radiosensitivity of colorectal cancer cells. Molecular medicine reports 2016, 13(3):2661-2670.
18. Chen P, Cescon M, Bonaldo P: Autophagy-mediated regulation of macrophages and its applications for cancer. Autophagy 2014, 10(2):192-200.
19. Cocquerelle C, Mascrez B, Hetuin D, Bailleul B: Mis-splicing yields circular RNA molecules. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1993, 7(1):155-160.
20. Xia S, Feng J, Lei L, Hu J, Xia L, Wang J, Xiang Y, Liu L, Zhong S, Han L et al: Comprehensive characterization of tissue-specific circular RNAs in the human and mouse genomes. Briefings in bioinformatics 2017, 18(6):984-992.
21. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013, 19(2):141-157.
22. Pervouchine DD: Circular exonic RNAs: When RNA structure meets topology. Biochimica et biophysica acta Gene regulatory mechanisms 2019, 1862(11-12):194384.
23. Guo JU, Agarwal V, Guo H, Bartel DP: Expanded identification and characterization of mammalian circular RNAs. Genome biology 2014, 15(7):409.
24. Yuan Y, Liu W, Zhang Y, Sun S: CircRNA circ_0026344 as a prognostic biomarker suppresses colorectal cancer progression via microRNA-21 and microRNA-31. Biochemical and biophysical research communications 2018, 503(2):870-875.
25. Biederbick A, Kern HF, Elsasser HP: Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. European journal of cell biology 1995, 66(1):3-14.
26. Yunna C, Mengru H, Lei W, Weidong C: Macrophage M1/M2 polarization. Eur J Pharmacol 2020, 877:173090.
27. Li XN, Wang ZJ, Ye CX, Zhao BC, Huang XX, Yang L: Circular RNA circVAPA is up-regulated and exerts oncogenic properties by sponging miR-101 in colorectal cancer. Biomed Pharmacother 2019, 112:108611.
28. Nguyen LT, Lee YH, Sharma AR, Park JB, Jagga S, Sharma G, Lee SS, Nam JS: Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2017, 21(2):205-213.
29. Liu Y, Gong W, Yang ZY, Zhou XS, Gong C, Zhang TR, Wei X, Ma D, Ye F, Gao QL: Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer. Apoptosis : an international journal on programmed cell death 2017, 22(4):544-557.
30. Zhou J, Li LU, Fang LI, Xie H, Yao W, Zhou X, Xiong Z, Wang LI, Li Z, Luo F: Quercetin reduces cyclin D1 activity and induces G1 phase arrest in HepG2 cells. Oncology letters 2016, 12(1):516-522.
31. Chen P, Bonaldo P: Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. International review of cell and molecular biology 2013, 301:1-35.
32. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141(1):39-51.
33. Bingle L, Lewis CE, Corke KP, Reed MW, Brown NJ: Macrophages promote angiogenesis in human breast tumour spheroids in vivo. British journal of cancer 2006, 94(1):101-107.
34. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine 2004, 351(27):2817-2826.
35. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England journal of medicine 2004, 351(21):2159-2169.
36. Yang Y, Wei S, Chu K, Li Q, Zhou Y, Ma Y, Xue L, Tian H, Tao S: Upregulation of autophagy in M2 macrophage by vitamin D alleviates crystalline silica-induced pulmonary inflammatory damage. Ecotoxicol Environ Saf 2021, 225:112730.
37. Yang S, Zhang X, Zhang H, Lin X, Chen X, Zhang Y, Lin X, Huang L, Zhuge Q: Dimethyl itaconate inhibits LPSinduced microglia inflammation and inflammasomemediated pyroptosis via inducing autophagy and regulating the Nrf2/HO1 signaling pathway. Mol Med Rep 2021, 24(3).
38. Xue X, Fei X, Hou W, Zhang Y, Liu L, Hu R: miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer letters 2018, 412:170-178.
39. Hu K, Mu X, Kolibaba H, Yin Q, Liu C, Liang X, Lu J: Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation. Saudi journal of biological sciences 2018, 25(5):975-981.
40. Zhang S, Liu L, Lv Z, Li Q, Gong W, Wu H: MicroRNA-342-3p Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Astrocyte-Elevated Gene-1 (AEG-1). Oncology research 2017, 25(9):1505-1515.
41. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, Xie K: Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. Journal of experimental & clinical cancer research : CR 2012, 31:97.
42. Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A: FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2016, 22(19):4947-4957.
43. Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H: Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. American journal of translational research 2014, 6(4):391-401.
44. Fang Z, Gong C, Yu S, Zhou W, Hassan W, Li H, Wang X, Hu Y, Gu K, Chen X et al: NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer letters 2018, 415:58-72.
45. Guo H, Zhang X, Chen Q, Bao Y, Dong C, Wang X: miR-132 suppresses the migration and invasion of lung cancer cells by blocking USP9X-induced epithelial-mesenchymal transition. American journal of translational research 2018, 10(1):224-234.
46. Wang YZ, Han JJ, Fan SQ, Yang W, Zhang YB, Xu TJ, Xu GM: miR-132 weakens proliferation and invasion of glioma cells via the inhibition of Gli1. European review for medical and pharmacological sciences 2018, 22(7):1971-1978.
47. Renjie W, Haiqian L: MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer letters 2015, 356(2 Pt B):568-578.
48. Zheng YB, Luo HP, Shi Q, Hao ZN, Ding Y, Wang QS, Li SB, Xiao GC, Tong SL: miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World journal of gastroenterology 2014, 20(21):6515-6522.
49. Wei XC, Lv ZH: MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGFbeta1/Smad2 signaling pathway in human bladder cancer. OncoTargets and therapy 2019, 12:5937-5945.
50. Liu Y, Zhang M: miR-132 Regulates Adriamycin Resistance in Colorectal Cancer Cells Through Targeting Extracellular Signal-Regulated Kinase 1. Cancer biotherapy & radiopharmaceuticals 2019, 34(6):398-404.
51. Walsh MD, Young JP, Leggett BA, Williams SH, Jass JR, McGuckin MA: The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas. Human pathology 2007, 38(6):883-892.